http://groups.google.com/group/sci.life-extension/browse_thread/thread/8f37e4036792d500?hl=en
topically applied 14-membered-ring macrolide antibiotic roxithromycin
(RXM - inhibits T-cell responses to mitogens and production of IL-2,
IL-5; also inhibits TGF-beta; inhibiting IL-5 and IL-6 would inhibit the
entry into early catagen that they provoke) restores hair growth and
blocks greying; RXM has effects on Langerhans cells, keratinocytes and
T-cells; one third patients showed dramatic results; one third showed
more than slight improvement after six months
<http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&Produkt
Nr=224164&Ausgabe=231841&ArtikelNr=92842&filename=92842.pdf> (for
clinical trials see <http://www.clinicaltrials.gov.ct/show/NCT00197379>
roxithromycin (RXM) antagonizes catagen induction in murine and human
hair follicles; RXM is a 14-member macrolide antibiotics, with a variety
of bioregulatory functions including anti-apoptotic activity in
keratinocytes, so it has been used for many skin diseases; human and
murine hair follicle bulbs treated with RXM in vitro were protected from
the inhibitory effect of IFN-gamma on keratinocyte proliferation and
subsequent induction of apoptosis; RXM increased hair elongation and
inhibited catagen-like changes in the hair bulb; in androgenetic
alopecia, dihydrotestosterone signals apoptosis in dermal papilla cells
in susceptible individuals, resulting in premature termination of anagen
and early entry into catagen; a topical 5% RXM solution effectively
restored hair growth in about half of individuals with AGA without any
local or systemic adverse effects [PMID 18820941]
contatto facebook: juliensorel@fastwebnet.it